---
schema_version: "secwatch.filing_event.v1"
accession: "0001493152-22-030706"
form_type: "8-K"
ticker: "VVOS"
cik: "0001716166"
company_name: "Vivos Therapeutics, Inc."
filed_at: "2022-11-04T23:59:59+00:00"
generated_at: "2026-06-22T07:08:58.185208+00:00"
event_type: "regulatory"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Vivos Therapeutics receives Nasdaq delisting notice for bid price below $1.00

## Summary
- Received deficiency notice on Nov 3, 2022 for bid price below $1.00 for 30 consecutive days (Sep 22–Nov 2, 2022).
- Has 180 days, until May 2, 2023, to regain compliance with closing bid ≥ $1.00 for 10 consecutive business days.
- If not cured, may qualify for additional 180-day grace period if meeting other listing standards.
- Management intends to resolve deficiency to maintain listing on Nasdaq Capital Market.

## SEC filing metadata
- accession: 0001493152-22-030706
- form_type: 8-K
- ticker: VVOS
- cik: 0001716166
- company_name: Vivos Therapeutics, Inc.
- filed_at: 2022-11-04T23:59:59+00:00
- event_type: regulatory
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 3.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1716166/000149315222030706/0001493152-22-030706-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1716166/000149315222030706/form8-k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001493152-22-030706
- JSON: https://secwatch.observer/filing/0001493152-22-030706.json
- Plain text: https://secwatch.observer/filing/0001493152-22-030706.txt

## Key facts
- Listing & Compliance Notices
  Vivos Therapeutics, Inc. received a nasdaq deficiency notice notice regarding minimum bid price (rules 5550(a)(2)).
  - Exchange: nasdaq
  - Notice: deficiency notice
  - Deficiency: minimum bid price
  - Rules: 5550(a)(2)
  source text: November 3, 2022, Vivos Therapeutics, Inc. (the “Company”) received a staff deficiency notice from The Nasdaq Stock Market (“Nasdaq”) indicating that, because the closing bid price for the Company’s common stock has fallen below $1.00 per share for 30 consecutive business days (September 22, 2022 through November 2, 2022), the Company no longer complies with the minimum bid price requirement for continued listing on the Nasdaq Capital Market under Rule 5550(a)(2) of the Nasdaq Listing Rules. Nasdaq’s notice has no immediate effect on the listing of the Company’s common stock on the Nasdaq Capi
  evidence_url: https://www.sec.gov/Archives/edgar/data/1716166/000149315222030706/0001493152-22-030706-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.